Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s shares dropped 1.79% to $110.86. The company on Dec. 15 announced that David Altshuler, M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard University and the Massachusetts Institute of Technology, where he has served as Deputy Director and Chief Academic Officer since 2009. Dr. Altshuler is also currently a Professor of Genetics and Medicine at Harvard Medical School and an Adjunct Professor of Biology at the Massachusetts Institute of Technology and has been an attending physician at the Massachusetts General Hospital.
Should Investors Buy VRTX After The Recent Development? Find Out Here
Exelixis, Inc. (NASDAQ:EXEL)’s shares dropped 3.68% to $1.31. The company on Dec. 15 announced its collaborator Genentech, a member of the Roche Group, has completed the filing of its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year.
Is EXEL Going To Rise or Fall After Today’s Price Action? Find Out Here
Alexion Pharmaceuticals, Inc.(NASDAQ:ALXN)’s shares dropped 2.99% to $177.73. The company on Dec. 15 announced that the Company’s Board of Directors has authorized a new share repurchase program of up to $500 million. The new share repurchase program will take effect upon completion of the Company’s current program, which has approximately $22 million remaining of its previously authorized $400 million.
Can Traders Buy ALXN After The Solid Rally? Get Free Trend Analysis Here
Under the program, purchases may be made from time to time on the open market, including through10b5-1 trading plans, or through privately negotiated transactions, block transactions, or other techniques, as determined by the Company’s management and in accordance with prevailing market conditions and the requirements of the Securities and Exchange Commission.
About thenextbigtrade.com
thenextbigtrade.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. thenextbigtrade.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
Disclaimer
The assembled information disseminated by thenextbigtrade.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. thenextbigtrade.com does expect that investors will buy and sell securities based on information assembled and presented in thenextbigtrade.com. PLEASE always do your own due diligence, and consult your financial advisor.
]]>